Low recurrence of preexisting extrahepatic malignancies after liver transplantation.
Standard
Low recurrence of preexisting extrahepatic malignancies after liver transplantation. / Benten, Daniel; Sterneck, Martina; Panse, Jens; Rogiers, Xavier; Lohse, Ansgar W.
In: LIVER TRANSPLANT, Vol. 14, No. 6, 6, 2008, p. 789-798.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Low recurrence of preexisting extrahepatic malignancies after liver transplantation.
AU - Benten, Daniel
AU - Sterneck, Martina
AU - Panse, Jens
AU - Rogiers, Xavier
AU - Lohse, Ansgar W.
PY - 2008
Y1 - 2008
N2 - The incidence of de novo malignancies is increased in organ transplant recipients, and patients with hepatic carcinomas are at high risk for tumor recurrence after liver transplantation. Data about recurrent cancer after orthotopic liver transplantation (OLT) in patients with a history of nonhepatic malignancy are very limited. We retrospectively analyzed data from 606 adult OLT recipients and identified 37 patients (6.1%) with a preexisting extrahepatic malignancy. In the same group, 43 patients (7.0%) developed de novo cancer. Preexisting malignancies included 26 solid tumors and 11 hematological malignancies, including 7 patients with Budd-Chiari syndrome due to myeloproliferative disorders (MPDs). Patients had been selected for OLT because of the expected good prognosis of their preexisting malignancy. Except for 3 patients, recipients were tumor-free at OLT. The median interval from tumor diagnosis to OLT was 44 months (range,
AB - The incidence of de novo malignancies is increased in organ transplant recipients, and patients with hepatic carcinomas are at high risk for tumor recurrence after liver transplantation. Data about recurrent cancer after orthotopic liver transplantation (OLT) in patients with a history of nonhepatic malignancy are very limited. We retrospectively analyzed data from 606 adult OLT recipients and identified 37 patients (6.1%) with a preexisting extrahepatic malignancy. In the same group, 43 patients (7.0%) developed de novo cancer. Preexisting malignancies included 26 solid tumors and 11 hematological malignancies, including 7 patients with Budd-Chiari syndrome due to myeloproliferative disorders (MPDs). Patients had been selected for OLT because of the expected good prognosis of their preexisting malignancy. Except for 3 patients, recipients were tumor-free at OLT. The median interval from tumor diagnosis to OLT was 44 months (range,
M3 - SCORING: Zeitschriftenaufsatz
VL - 14
SP - 789
EP - 798
JO - LIVER TRANSPLANT
JF - LIVER TRANSPLANT
SN - 1527-6465
IS - 6
M1 - 6
ER -
